"Future research on screening for atrial fibrillation should focus on the selection of patients with the highest risk of having or developing undetected atrial fibrillation and the role of repeated or prolonged monitoring," Dr. Steven B. Uittenbogaart of the University of Amsterdam in The Netherlands and colleagues conclude in The BMJ.
The Screening for Atrial Fibrillation in the Elderly (SAFE) trial, published in 2007, found that opportunistic screening by pulse palpation detected more AF cases than usual care, the authors note. However, the findings haven't been replicated in randomized trials, they add, and it's unclear whether increased detection affects clinical endpoints including stroke and death.
In the new Detecting and Diagnosing Atrial Fibrillation (D2AF) study, Dr. Uittenbogaart and colleagues randomized primary-care practices to intent-to-screen (47) or usual care (49), randomly sampling 200 patients from each practice.
Screening consisted of pulse palpation, electronic blood pressure measurement with an AF algorithm, and electrocardiography (ECG) with a hand-held single-lead device. Patients with at least one positive test underwent 12-lead ECG. If the test did not find AF, they were invited to undergo Holter monitoring.
The intention-to-screen group included more than 9,000 patients, 4,106 of whom were screened, and slightly more patients who received usual care. There were 144 new AF cases diagnosed in the intent-to-screen group (1.62%), versus139 (1.53%) in the usual care group, a non-significant difference.
Among the patients who were screened, 488 had at least one positive index test, and 448 underwent 12-lead ECG, which diagnosed 26 patients with AF. Among patients with negative ECGs, 266 underwent Holter monitoring for two weeks, which identified four additional AF cases.
"Our findings showed that one time point screening missed silent and paroxysmal atrial fibrillation," Dr. Uittenbogaart and colleagues note.
"The uptake of continuous rhythm monitoring as a means of screening for atrial fibrillation might be more effective with new and wireless technologies, such as smart watches or wireless patches," they add.
Dr. Uittenbogaart was not available for an interview by press time.
By Reuters Staff
SOURCE: https://bit.ly/2RWrYOo BMJ, online September 16, 2020.
Posted on
Previous Article
« Telemedicine promising for blood pressure management, but many challenges remain Next Article
SGLT2 inhibitors may lower the risk of major cardiovascular events »
« Telemedicine promising for blood pressure management, but many challenges remain Next Article
SGLT2 inhibitors may lower the risk of major cardiovascular events »
Related Articles
September 8, 2020
Factor V Leiden mutation linked to atrial fibrillation
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com